Condition
TNBC, Triple Negative Breast Cancer
ClinicalTrials.gov condition label
Clinical trials
18 shownQUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast CancerNCT07601178 · 2026-04-17
RECRUITING177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid TumorsNCT07189871 · 2026-02-23
RECRUITINGStudy of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.NCT07638852 · 2026-02-02
RECRUITINGA Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast CanceNCT07321015 · 2026-01-20
RECRUITINGNeoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast CancerNCT07457359 · 2026-01-04
RECRUITINGMRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBCNCT07327021 · 2025-11-11
RECRUITINGA Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBCNCT07178171 · 2025-11-06
RECRUITINGPredicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)NCT07327489 · 2025-04-14
RECRUITINGQL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBCNCT06786026 · 2024-10-09
RECRUITINGNeoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)NCT06682195 · 2024-10-09
RECRUITING177Lu-anti-PD-L1 sdAb in Metastatic Solid TumorsNCT06305962 · 2024-06-03
RECRUITINGNeoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast CancerNCT06220214 · 2024-03-06
RECRUITINGComparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBCNCT07523789 · 2026-05-01
NOT_YET_RECRUITINGTREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast CancerNCT07271992 · 2025-12-15
NOT_YET_RECRUITINGNeoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast CancerNCT06977542 · 2025-06-01
NOT_YET_RECRUITINGQL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast CancerNCT06404736 · 2024-05-07
NOT_YET_RECRUITINGA Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin LymphomaNCT03207867 · 2017-08-28
TERMINATEDAn Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)NCT07536815
AVAILABLECommon interventions
BevacizumabDRUG2177Lu-BetaBartDRUG1177Lu-RAD204DRUG1AdebelimabDRUG1Albumin-bound paclitaxelDRUG1BetaBart + unlabeled BetaBartDRUG1BiopsyPROCEDURE1Bispecific antibody (bsAb) targeting PD-1 and CLTA-4DRUG1CarboplatinDRUG1Carboplatin (AUC 5)DRUG1CEDBTDIAGNOSTIC_TEST1CEDMDIAGNOSTIC_TEST1Chemotherapy switchDRUG1Cisplatin or carboplatinDRUG1CyclophosphamideDRUG1Fluzoparib MonotherapyDRUG1IvonescimabDRUG1leronlimab (PRO 140)DRUG1Nab paclitaxelDRUG1Nab-paclitaxelDRUG1Neoadjuvant chemotherapy combined with ToripalimabDRUG1NIR178DRUG1Omnipaque 350mgI/mL Solution for InjectionDRUG1PDR001DRUG1PirarubicinDRUG1
Leading sponsors
Fudan University4Radiopharm Theranostics, Ltd2Alison Stopeck1CytoDyn, Inc.1Elephas1First Affiliated Hospital of Zhejiang University1First Hospital of China Medical University1Jiangsu Cancer Institute & Hospital1Novartis Pharmaceuticals1Second Affiliated Hospital, Zhejiang University, School of Medicine1Tel-Aviv Sourasky Medical Center1The First Affiliated Hospital with Nanjing Medical University1Tianjin Medical University Cancer Institute and Hospital1Xijing Hospital1
Trial status mix
RECRUITING12
NOT_YET_RECRUITING4
AVAILABLE1
TERMINATED1
Phase mix
PHASE212
EARLY_PHASE12
PHASE12
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.